fenfluramine has been researched along with Weight Reduction in 111 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After a one month 'run in' phase and six months treatment, weight loss in the dexfenfluramine group was significantly greater than placebo, 9." | 9.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "To investigate whether a serotoninergic drug such as dexfenfluramine (dF) may have some beneficial effects on energy expenditure (EE) during therapeutic weight reduction, a 3-month study was conducted in a double-blind, placebo-controlled trial." | 9.08 | Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. ( De Leeuw, IH; Steijaert, MC; Van Gaal, LF; Vansant, GA, 1995) |
| "To identify parameters predictive of weight loss during treatment with d-fenfluramine." | 9.08 | Predictors of weight loss during treatment with d-fenfluramine. ( Hopman, E; Meinders, AE; Pijl, H; Toornvliet, AC; Westendorp, RG, 1997) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 9.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| "In previous separate studies, dexfenfluramine (DF) and ephedrine/caffeine (EC) have been shown to promote weight loss in obese patients as compared with placebo." | 9.07 | Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. ( Ahlstrøm, F; Breum, L; Frimodt-Møller, J; Pedersen, JK, 1994) |
| "The purpose of this study was to determine the effects of dexfenfluramine on body weight and post-prandial thermogenesis in obese subjects." | 9.07 | Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. ( Lafreniere, F; Lambert, J; Rasio, E; Serri, O, 1993) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (D-F)." | 9.07 | Body weight evolution during dexfenfluramine treatment after initial weight control. ( Finer, N, 1992) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 8.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 7.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| " In order to clarify whether a similar relation exists in obesity and to elucidate the long-term effect of dexfenfluramine (dF) on plasma amino acid profiles and macronutrient selection, we examined 29 obese patients participating in a 12 months double-blind weight loss trial with either dexfenfluramine (dF) (30 mg/day) or placebo (PL) in conjunction with 4." | 7.69 | Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. ( Andersen, T; Astrup, A; Breum, L; Møller, SE, 1996) |
| " To examine whether weight loss produced by serotoninergic drugs involves a selective reduction in CHO intake, obese females who consumed at least 30% of their daily calories from CHO-rich snacks were treated with dexfenfluramine ([DF] 15 mg b." | 7.68 | Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. ( Berry, E; Gleason, R; Goldberg, H; Kahne, M; McDermott, J; Tsay, R; Wurtman, J; Wurtman, R, 1993) |
| "Dexfenfluramine treatment was not associated with greater loss of weight." | 6.68 | Evaluation of dexfenfluramine in a weight loss program for obese infertile women. ( Clark, A; Galletly, C; Tomlinson, L, 1996) |
| "In the previous dF treated patients weight loss after re-introduction of dF was 3." | 6.68 | The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 6.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 6.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 6.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| "To determine the echocardiographic changes over time of valvular heart lesions in patients who took the weight loss drugs fenfluramine and phentermine." | 5.09 | Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. ( Bailey, KR; Connolly, HM; Grogan, M; Hensrud, DD; Jensen, MD; Miller, FA, 1999) |
| " In Study 2, 19 men and 23 women took part in a 15-week weight loss program that consisted of drug therapy (fenfluramine, 60 mg/day) or placebo coupled to an energy-restricted diet (-2930 kJ/day)." | 5.09 | Fasting insulin levels influence plasma leptin levels independently from the contribution of adiposity: evidence from both a cross-sectional and an intervention study. ( Alméras, N; Bouchard, C; Després, JP; Doucet, E; Mauriège, P; Richard, D; St-Pierre, S; Tremblay, A, 2000) |
| "To investigate whether a serotoninergic drug such as dexfenfluramine (dF) may have some beneficial effects on energy expenditure (EE) during therapeutic weight reduction, a 3-month study was conducted in a double-blind, placebo-controlled trial." | 5.08 | Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. ( De Leeuw, IH; Steijaert, MC; Van Gaal, LF; Vansant, GA, 1995) |
| "Dexfenfluramine aids weight loss and improves glycemic control in obese Chinese NIDDM patients over a 3- to 6-month period." | 5.08 | Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. ( Chan, JC; Chow, CC; Cockram, CS; Ko, GT; Tsang, LW; Yeung, VT, 1997) |
| "To investigate the effect of the serotonin receptor agonist dexfenfluramine on eating habits and weight loss in ambulatory, android type, moderately obese patients with an overconsumption of snacks." | 5.08 | The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. ( Drent, ML; Koppeschaar, HP; Lutterman, JA; Nieuwenhuyzen Kruseman, AC; van der Veen, EA; Zelissen, PM, 1995) |
| " We have evaluated the weight loss of a selective inhibitor of serotonin uptake, fluoxetine, alone as compared with combined therapeutic trial with another serotoninergic drug, dexfenfluramine." | 5.08 | The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. ( Halpern, A; Lima, N; Medeiros-Neto, G; Pedrinola, F; Sztejnsznajd, C, 1996) |
| "After a one month 'run in' phase and six months treatment, weight loss in the dexfenfluramine group was significantly greater than placebo, 9." | 5.08 | Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. ( Caterson, ID; O'Connor, HT; Richman, RM; Steinbeck, KS, 1995) |
| "To identify parameters predictive of weight loss during treatment with d-fenfluramine." | 5.08 | Predictors of weight loss during treatment with d-fenfluramine. ( Hopman, E; Meinders, AE; Pijl, H; Toornvliet, AC; Westendorp, RG, 1997) |
| "The aim of this study was to investigate the potential of dexfenfluramine (dF) for reducing cardiovascular risk factors and improving compliance towards diet in a group of young patients hospitalized for essential obesity of high degree (BMI > or = 35)." | 5.08 | Dexfentluramine in the treatment of juvenile obesity. ( Ardizzi, A; Grugni, G; Guzzaloni, G; Morabito, F; Moro, D, 1997) |
| "To assess the effect of dexfenfluramine on weight loss in obese adolescents, a group of 19 obese girls and boys was treated with a low calorie diet, supplemented with dexfenfluramine." | 5.08 | [Efficacy and safety of dexfenfluramine treatment in obese adolescents]. ( Koehler, B; Małecka-Tendera, E; Muchacka, M; Trzciakowska, A; Wazowski, R, 1996) |
| "Dexfenfluramine is effective in achieving weight loss and also improved diabetic control in obese type II diabetics over a three-month period." | 5.07 | Dexfenfluramine in type II diabetes: effect on weight and diabetes control. ( Davis, TM; Findlater, P; Stein, GR; Stewart, GO, 1993) |
| "Dexfenfluramine has been shown to promote weight loss in overweight people." | 5.07 | The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. ( Molyneaux, LM; Overland, JE; Willey, KA; Yue, DK, 1992) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (D-F)." | 5.07 | Body weight evolution during dexfenfluramine treatment after initial weight control. ( Finer, N, 1992) |
| "The purpose of this study was to determine the effects of dexfenfluramine on body weight and post-prandial thermogenesis in obese subjects." | 5.07 | Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. ( Lafreniere, F; Lambert, J; Rasio, E; Serri, O, 1993) |
| "The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additional group therapy." | 5.07 | Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. ( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994) |
| "In previous separate studies, dexfenfluramine (DF) and ephedrine/caffeine (EC) have been shown to promote weight loss in obese patients as compared with placebo." | 5.07 | Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. ( Ahlstrøm, F; Breum, L; Frimodt-Møller, J; Pedersen, JK, 1994) |
| " Pharmacological treatment of obesity has evolved in recent years with the development and licensing of potent serotonin agonists, such as dexfenfluramine (dF), acting as nonstimulant anorectic agents." | 5.07 | Drug therapy after very-low-calorie diets. ( Finer, N; Finer, S; Naoumova, RP, 1992) |
| "The efficacy of dexfenfluramine in inducing weight loss and its clinical acceptability were assessed in two studies carried out in a hospital obesity clinic and general practitioner's office." | 5.06 | Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. ( Craddock, D; Finer, N; Keen, H; Lavielle, R, 1988) |
| "To evaluate whether the inhibitory control of TSH and the stimulatory control of prolactin (PRL) secretion exerted by endogenous serotonin was altered in obesity, 22 obese men and 10 normal controls were tested with TRH (200 micrograms IV bolus) in the presence (experimental test) and absence (control test) of the serotonergic agonist fenfluramine (60 mg PO 90 min before TRH)." | 5.06 | Serotonergic control of TSH and PRL secretion in obese men. ( Camellini, L; Capretti, L; Coiro, V; Davoli, C; Marchesi, C; Passeri, M; Rossi, G; Roti, E; Speroni, G; Volpi, R, 1990) |
| "Three studies have been undertaken to investigate why there are individual differences in the response to d-fenfluramine with respect to food intake and hunger in the short term and on body weight loss in the long term." | 5.06 | Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration. ( Campbell, DB; Gordon, BH; Ings, RM; Richards, R; Taylor, DW, 1988) |
| " The USA, the European Union and Norway have approved orlistat, a pancreatic lipase inhibitor for weight reduction for up to two years." | 4.80 | [The obesity epidemics--do diet pills have a place in the treatment?]. ( Birkeland, KI; Tonstad, S, 2000) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 4.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day." | 4.79 | Sibutramine--a review of clinical efficacy. ( Lean, ME, 1997) |
| "d Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity." | 4.79 | Clinical studies with dexfenfluramine: from past to future. ( Guy-Grand, B, 1995) |
| "This is a report of health-related quality of life (HRQOL) changes in obese patients completing at least 1 year of outpatient treatment in a weight reduction program combining phentermine-fenfluramine and dietary counseling." | 3.71 | The relationship between health-related quality of life and weight loss. ( Crosby, RD; Hartley, GG; Kolotkin, RL; Nicol, S; Williams, GR, 2001) |
| "Phentermine and fenfluramine are widely used in the treatment of obesity." | 3.70 | Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. ( Katz, DA; Maloney, MJ; McConville, BJ; Sutkamp, JC, 1999) |
| "22 severe binge eaters, 17 moderate binge eaters, and 16 non-binge eaters received phentermine resin 15mg/day and dl-fenfluramine 20mg three times daily over a 6 month period for weight loss." | 3.70 | Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. ( Alger, SA; Cerulli, J; Fein, S; Howard, L; Malone, M, 1999) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Seventeen subjects (10 men and seven women) took part in a 15 week weight loss program which consisted of drug therapy (fenfluramine 60 mg/day) or placebo coupled to an energy restriction (-2930 kJ/day; phase 1) followed by an 18 week low-fat diet-exercise follow-up (phase 2)." | 3.70 | Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. ( Alméras, N; Doucet, E; Imbeault, P; Mauriège, P; Richard, D; St-Pierre, S; Tremblay, A, 2000) |
| " In the first phase, a non-macronutrient-specific dietary restriction of about 700 kcal/day was prescribed to induce weight loss over 15 weeks, with either fenfluramine or placebo." | 3.70 | Metabolic fitness in active reduced-obese individuals. ( Després, JP; Doucet, E; Imbeault, P; Mauriège, P; Richard, D; Tremblay, A, 1999) |
| "To assess weight loss, as well as the prevalence of valvular heart disease, in 21 obese women who completed 2 years of treatment by fenfluramine and phentermine (fen-phen) in June 1997." | 3.70 | The fen-phen finale: a study of weight loss and valvular heart disease. ( Aber, JL; Berkowitz, RI; Foster, GD; Silvestry, F; St John Sutton, MG; Stunkard, AJ; Vogt, RA; Wadden, TA, 1998) |
| "The media has been rife with stories about dexfenfluramine, the newest anti-obesity drug." | 3.69 | Iowa patients want new anti-obesity drug. ( Belling, W, 1996) |
| " In order to clarify whether a similar relation exists in obesity and to elucidate the long-term effect of dexfenfluramine (dF) on plasma amino acid profiles and macronutrient selection, we examined 29 obese patients participating in a 12 months double-blind weight loss trial with either dexfenfluramine (dF) (30 mg/day) or placebo (PL) in conjunction with 4." | 3.69 | Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. ( Andersen, T; Astrup, A; Breum, L; Møller, SE, 1996) |
| "We determined the effects of D-fenfluramine treatment on the changes in vascular reactivity induced by aging." | 3.68 | Effect of aging and drug-induced weight reduction on rat vascular reactivity. ( Boulanger, M; Duhault, J; Feletou, M; Moreau, N, 1993) |
| " To examine whether weight loss produced by serotoninergic drugs involves a selective reduction in CHO intake, obese females who consumed at least 30% of their daily calories from CHO-rich snacks were treated with dexfenfluramine ([DF] 15 mg b." | 3.68 | Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. ( Berry, E; Gleason, R; Goldberg, H; Kahne, M; McDermott, J; Tsay, R; Wurtman, J; Wurtman, R, 1993) |
| "Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective." | 2.69 | Pharmacologic induction of weight loss to treat type 2 diabetes. ( Bantle, JP; Kwong, CA; Raatz, SK; Redmon, JB; Swanson, JE; Thomas, W, 1999) |
| "Initial weight loss has been used as a predictor of long-term response to obesity drugs." | 2.69 | Initial weight loss as a predictor of response to obesity drugs. ( Atkinson, RL; Blank, RC; Dhurandhar, NV; Schumacher, D, 1999) |
| "Dexfenfluramine was most effective in the short term, behavioural therapy useful long term but only in those who remained within the group; home visits offered no advantage." | 2.68 | The comparison of four weight reduction strategies aimed at overweight diabetic patients. ( Jung, RT; Leese, GP; Manning, RM; Newton, RW, 1995) |
| "Dexfenfluramine treatment was not associated with greater loss of weight." | 2.68 | Evaluation of dexfenfluramine in a weight loss program for obese infertile women. ( Clark, A; Galletly, C; Tomlinson, L, 1996) |
| "In the previous dF treated patients weight loss after re-introduction of dF was 3." | 2.68 | The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity. ( Adler, G; Ditschuneit, HH; Flechtner-Mors, M, 1996) |
| " The apparently complex influence of weight loss on prolactin response to serotonergic challenge remains to be clarified as well as the role played by the bioavailability of the challenge drug and its metabolite." | 2.67 | Hormone responses to fenfluramine and placebo challenge in endogenous depression. ( Cooper, TB; Gillon, D; Kindler, S; Lerer, B; Lichtenberg, P; Newman, ME; Shapira, B, 1992) |
| "Dexfenfluramine- and placebo-treated patients achieved a similar weight loss (greater than 10% of initial weight, by 39." | 2.67 | Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. ( Kok, AM; Mathus-Vliegen, EM; Res, AM; van de Voorde, K, 1992) |
| "Dexfenfluramine (dF) was compared to placebo as adjuvant to a very energy-restricted diet (1." | 2.67 | Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial. ( Andersen, T; Astrup, A; Quaade, F, 1992) |
| " Dosing changes were based on an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects." | 2.67 | Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. ( Moscucci, M; Schuster, B; Stein, EC; Sundaresan, PR; Weintraub, M, 1992) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 2.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| " In conclusion, dextrafenfluramine was proved to be in short term trials an effective and safe tool in overweight control in obese patients." | 2.66 | Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. ( Baggio, B; Bruni, R; Crepaldi, G; Enzi, G; Inelmen, EM, 1988) |
| "Obesity is a major health concern which must be treated." | 2.40 | Pharmacological approaches to intervention. ( Guy-Grand, B, 1997) |
| "Obesity is a chronic disease, which similar to diabetes and hypertension, requires long-term treatment." | 2.40 | Obesity. ( Aronne, LJ, 1998) |
| "Dexfenfluramine has been demonstrated to produce decreases in daily energy intake varying between 13 and 25% depending on the time for which the drug has been administered." | 2.38 | Dexfenfluramine and appetite in humans. ( Blundell, JE; Hill, AJ, 1992) |
| "The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration." | 2.38 | Appraisal of the clinical value of serotoninergic drugs. ( Hodge, J; Munro, JF; Scott, C, 1992) |
| "Two patients developed fulminant hepatic failure: 1 patient required liver transplantation, and the other patient died." | 1.32 | Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido. ( Adachi, M; Horie, Y; Ishii, H; Kato, S; Kobayashi, H; Saito, H; Yoshioka, M, 2003) |
| " dosing for measurement of obesity-related parameters." | 1.32 | Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. ( Bennani, YL; Bush, EN; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Jacobson, P; Knourek-Segel, V; Krueger, KM; Nuss, ME; Pan, JB; Shapiro, R; Witte, DG; Yao, BB, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (7.21) | 18.7374 |
| 1990's | 76 (68.47) | 18.2507 |
| 2000's | 20 (18.02) | 29.6817 |
| 2010's | 5 (4.50) | 24.3611 |
| 2020's | 2 (1.80) | 2.80 |
| Authors | Studies |
|---|---|
| Odi, R | 1 |
| Invernizzi, RW | 1 |
| Gallily, T | 1 |
| Bialer, M | 1 |
| Perucca, E | 1 |
| Patel, M | 1 |
| Daboul, J | 1 |
| Iftikhar, S | 1 |
| Burmeister, C | 1 |
| Ambati, A | 1 |
| Moukarbel, G | 1 |
| Assaly, R | 1 |
| Carmody, JS | 1 |
| Ahmad, NN | 1 |
| Machineni, S | 1 |
| Lajoie, S | 1 |
| Kaplan, LM | 2 |
| Bray, GA | 3 |
| Vocks, S | 1 |
| Tuschen-Caffier, B | 1 |
| Pietrowsky, R | 1 |
| Rustenbach, SJ | 1 |
| Kersting, A | 1 |
| Herpertz, S | 1 |
| Astrup, A | 3 |
| Xu, Y | 1 |
| Jones, JE | 1 |
| Lauzon, DA | 1 |
| Anderson, JG | 1 |
| Balthasar, N | 1 |
| Heisler, LK | 1 |
| Zinn, AR | 1 |
| Lowell, BB | 1 |
| Elmquist, JK | 1 |
| Doucet, E | 7 |
| Imbeault, P | 6 |
| St-Pierre, S | 4 |
| Alméras, N | 7 |
| Mauriège, P | 7 |
| Després, JP | 6 |
| Bouchard, C | 4 |
| Tremblay, A | 10 |
| Adachi, M | 1 |
| Saito, H | 1 |
| Kobayashi, H | 1 |
| Horie, Y | 1 |
| Kato, S | 1 |
| Yoshioka, M | 1 |
| Ishii, H | 1 |
| Hancock, AA | 1 |
| Bennani, YL | 1 |
| Bush, EN | 1 |
| Esbenshade, TA | 1 |
| Faghih, R | 1 |
| Fox, GB | 1 |
| Jacobson, P | 1 |
| Knourek-Segel, V | 1 |
| Krueger, KM | 1 |
| Nuss, ME | 1 |
| Pan, JB | 1 |
| Shapiro, R | 1 |
| Witte, DG | 1 |
| Yao, BB | 1 |
| Blanck, HM | 1 |
| Khan, LK | 1 |
| Serdula, MK | 1 |
| Atchley, DP | 1 |
| Eckel, LA | 1 |
| Whigham, LD | 1 |
| Dhurandhar, NV | 2 |
| Rahko, PS | 1 |
| Atkinson, RL | 2 |
| Yuen, YP | 1 |
| Lai, CK | 1 |
| Poon, WT | 1 |
| Ng, SW | 1 |
| Chan, AY | 1 |
| Mak, TW | 1 |
| Fernstrom, JD | 1 |
| Choi, S | 1 |
| Metz, L | 1 |
| Mercier, J | 1 |
| Joanisse, DR | 1 |
| Drent, ML | 2 |
| Zelissen, PM | 1 |
| Koppeschaar, HP | 1 |
| Nieuwenhuyzen Kruseman, AC | 1 |
| Lutterman, JA | 1 |
| van der Veen, EA | 2 |
| Manning, RM | 2 |
| Jung, RT | 2 |
| Leese, GP | 2 |
| Newton, RW | 2 |
| Feletou, M | 1 |
| Moreau, N | 1 |
| Boulanger, M | 1 |
| Duhault, J | 1 |
| Recasens, MA | 1 |
| Barenys, M | 1 |
| Sola, R | 1 |
| Blanch, S | 1 |
| Masana, L | 1 |
| Salas-Salvadó, J | 1 |
| O'Connor, HT | 1 |
| Richman, RM | 1 |
| Steinbeck, KS | 1 |
| Caterson, ID | 1 |
| Max, JP | 1 |
| Thystere, P | 1 |
| Chapleur-Chateau, M | 1 |
| Burlet, A | 1 |
| Nicolas, JP | 1 |
| Burlet, C | 1 |
| Rebuffé-Scrive, M | 1 |
| DePodesta, C | 1 |
| Van Gaal, LF | 1 |
| Vansant, GA | 1 |
| Steijaert, MC | 1 |
| De Leeuw, IH | 1 |
| Khan, M | 1 |
| Lum, CT | 1 |
| Rao, V | 1 |
| Bremer, JM | 1 |
| Scott, RS | 1 |
| Lintott, CJ | 1 |
| Pfohl, M | 1 |
| Luft, D | 1 |
| Blomberg, I | 1 |
| Schmülling, RM | 1 |
| Breum, L | 2 |
| Pedersen, JK | 1 |
| Ahlstrøm, F | 1 |
| Frimodt-Møller, J | 1 |
| Rowland, NE | 2 |
| Walsh, JP | 1 |
| Davis, TM | 2 |
| Stewart, GO | 2 |
| Stein, GR | 2 |
| Findlater, P | 2 |
| Wurtman, J | 1 |
| Wurtman, R | 1 |
| Berry, E | 1 |
| Gleason, R | 2 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Kahne, M | 1 |
| Tsay, R | 1 |
| Lafreniere, F | 1 |
| Lambert, J | 1 |
| Rasio, E | 1 |
| Serri, O | 1 |
| Mathus-Vliegen, LM | 1 |
| Res, AM | 2 |
| Del Ponte, A | 1 |
| D'Orazio, N | 1 |
| Di Giacomo, G | 1 |
| Tritella, T | 1 |
| Bitti, G | 1 |
| Martines, G | 1 |
| Møller, SE | 1 |
| Andersen, T | 2 |
| Ditschuneit, HH | 1 |
| Flechtner-Mors, M | 1 |
| Adler, G | 1 |
| Guy-Grand, B | 4 |
| Małecka-Tendera, E | 1 |
| Koehler, B | 1 |
| Muchacka, M | 1 |
| Wazowski, R | 1 |
| Trzciakowska, A | 1 |
| Adèr, HJ | 1 |
| Belling, W | 1 |
| van der Merwe, MT | 1 |
| Wing, JR | 1 |
| Celgow, LH | 1 |
| Gray, IP | 1 |
| Lönn, L | 1 |
| Joffe, BI | 1 |
| Lönnroth, PN | 1 |
| Toornvliet, AC | 2 |
| Pijl, H | 2 |
| Hopman, E | 2 |
| Elte-de Wever, BM | 1 |
| Meinders, AE | 2 |
| Galletly, C | 1 |
| Clark, A | 1 |
| Tomlinson, L | 1 |
| Pedrinola, F | 1 |
| Sztejnsznajd, C | 1 |
| Lima, N | 1 |
| Halpern, A | 1 |
| Medeiros-Neto, G | 1 |
| Lean, ME | 1 |
| Westendorp, RG | 1 |
| Wadden, TA | 3 |
| Berkowitz, RI | 3 |
| Vogt, RA | 2 |
| Steen, SN | 1 |
| Stunkard, AJ | 2 |
| Foster, GD | 3 |
| Grugni, G | 1 |
| Guzzaloni, G | 1 |
| Ardizzi, A | 1 |
| Moro, D | 1 |
| Morabito, F | 1 |
| Chow, CC | 1 |
| Ko, GT | 1 |
| Tsang, LW | 1 |
| Yeung, VT | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Garrett, SD | 1 |
| Cupp, MJ | 1 |
| Carmichael, HE | 1 |
| Swinburn, BA | 1 |
| Wilson, MR | 1 |
| Aronne, LJ | 1 |
| Pocock, SJ | 1 |
| Abdalla, M | 1 |
| Silvestry, F | 1 |
| St John Sutton, MG | 1 |
| Aber, JL | 2 |
| Cowley, G | 1 |
| Springen, K | 1 |
| Dionne, I | 1 |
| Katz, DA | 1 |
| Maloney, MJ | 1 |
| Sutkamp, JC | 1 |
| McConville, BJ | 1 |
| Silvestry, FE | 1 |
| Sutton, MG | 1 |
| Redmon, JB | 1 |
| Raatz, SK | 1 |
| Kwong, CA | 1 |
| Swanson, JE | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Ryan, DH | 3 |
| Helmcke, F | 1 |
| Sander, G | 1 |
| Volaufova, J | 1 |
| Greenway, F | 1 |
| Subramaniam, P | 1 |
| Glancy, DL | 1 |
| Lin, X | 1 |
| Levitsky, DA | 1 |
| King, JM | 1 |
| Campbell, TC | 1 |
| Alger, SA | 1 |
| Malone, M | 1 |
| Cerulli, J | 1 |
| Fein, S | 1 |
| Howard, L | 1 |
| Greenway, FL | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Richard, D | 4 |
| Hensrud, DD | 1 |
| Connolly, HM | 1 |
| Grogan, M | 1 |
| Miller, FA | 1 |
| Bailey, KR | 1 |
| Jensen, MD | 1 |
| Blank, RC | 1 |
| Schumacher, D | 1 |
| Poston, WS | 1 |
| Foreyt, JP | 1 |
| St Pierre, S | 1 |
| Tonstad, S | 1 |
| Birkeland, KI | 1 |
| Kolotkin, RL | 1 |
| Crosby, RD | 1 |
| Williams, GR | 1 |
| Hartley, GG | 1 |
| Nicol, S | 1 |
| Chevrier, J | 1 |
| Dewailly, E | 1 |
| Ayotte, P | 1 |
| Pascot, A | 1 |
| Quaade, F | 1 |
| Munro, JF | 2 |
| Cantley, P | 1 |
| Finer, N | 4 |
| Blundell, JE | 1 |
| Hill, AJ | 1 |
| Lichtenberg, P | 1 |
| Shapira, B | 1 |
| Gillon, D | 1 |
| Kindler, S | 1 |
| Cooper, TB | 1 |
| Newman, ME | 1 |
| Lerer, B | 1 |
| Weintraub, M | 5 |
| Mathus-Vliegen, EM | 1 |
| van de Voorde, K | 1 |
| Kok, AM | 1 |
| Sundaresan, PR | 4 |
| Madan, M | 2 |
| Schuster, B | 3 |
| Balder, A | 2 |
| Lasagna, L | 1 |
| Cox, C | 2 |
| Ginsberg, G | 1 |
| Stein, EC | 2 |
| Byrne, L | 1 |
| Moscucci, M | 1 |
| Willey, KA | 1 |
| Molyneaux, LM | 1 |
| Overland, JE | 1 |
| Yue, DK | 1 |
| Finer, S | 2 |
| Naoumova, RP | 2 |
| Scott, C | 1 |
| Hodge, J | 1 |
| O'Keane, V | 1 |
| Dinan, TG | 1 |
| Aman, MG | 1 |
| Kern, RA | 1 |
| Arnold, LE | 1 |
| McGhee, DE | 1 |
| Coiro, V | 1 |
| Passeri, M | 1 |
| Capretti, L | 1 |
| Speroni, G | 1 |
| Davoli, C | 1 |
| Marchesi, C | 1 |
| Rossi, G | 1 |
| Camellini, L | 1 |
| Volpi, R | 1 |
| Roti, E | 1 |
| Mitchell, P | 1 |
| Smythe, G | 1 |
| Ivković-Lazar, T | 1 |
| Stokić, E | 1 |
| Lepsanović, L | 1 |
| Apfelbaum, M | 1 |
| Crepaldi, G | 2 |
| Gries, A | 1 |
| Lefebvre, P | 1 |
| Turner, P | 1 |
| Carlton, J | 1 |
| O'Rourke, D | 1 |
| Wurtman, JJ | 1 |
| Wurtman, RJ | 1 |
| Chebli, R | 1 |
| Goodall, E | 1 |
| Oxtoby, C | 1 |
| Richards, R | 2 |
| Watkinson, G | 1 |
| Brown, D | 1 |
| Silverstone, T | 1 |
| Campbell, DB | 1 |
| Gordon, BH | 1 |
| Ings, RM | 1 |
| Taylor, DW | 1 |
| Enzi, G | 1 |
| Inelmen, EM | 1 |
| Bruni, R | 1 |
| Baggio, B | 1 |
| Craddock, D | 1 |
| Lavielle, R | 1 |
| Keen, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Abdominal Obesity as a Therapeutic Target: Long-term Benefits of Abdominal Fat Loss and Weight Stabilization in High-risk Abdominally Obese Dyslipidemic Patients With the Features of the Metabolic Syndrome (SYNERGIE Study)[NCT06158191] | 186 participants (Actual) | Interventional | 2004-03-26 | Completed | |||
| Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
| Hunger and Satiety Perception in Patients With Anorexia Nervosa[NCT02932046] | 47 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [NCT00000506] | Phase 2 | 0 participants | Interventional | 1983-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for fenfluramine and Weight Reduction
| Article | Year |
|---|---|
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know.
Topics: Animals; Drug Repositioning; Epilepsy; Fenfluramine; Humans; Randomized Controlled Trials as Topic; | 2021 |
Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Cognitive Beh | 2010 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
The development of tolerance to drugs that suppress food intake.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Huma | 2008 |
Clinical studies with dexfenfluramine: from past to future.
Topics: Appetite Depressants; Fenfluramine; Humans; Obesity; Weight Loss | 1995 |
Pharmacological approaches to intervention.
Topics: Anti-Obesity Agents; Appetite Depressants; Fenfluramine; Humans; Obesity; Phentermine; Time Factors; | 1997 |
Sibutramine--a review of clinical efficacy.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physio | 1997 |
The fenfluramine/phentermine combination for weight loss.
Topics: Appetite Depressants; Clinical Trials as Topic; Drug Therapy, Combination; Fenfluramine; Humans; Phe | 1997 |
Obesity.
Topics: Appetite Depressants; Behavior; Body Mass Index; Diet, Reducing; Exercise; Female; Fenfluramine; Hum | 1998 |
Scientific and legal issues in fenfluramine/dexfenfluramine litigation.
Topics: Anti-Obesity Agents; Dexfenfluramine; Fenfluramine; Heart Valve Diseases; Humans; Hypertension, Pulm | 2000 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obe | 2000 |
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluram | 2000 |
The management of obesity. One view.
Topics: Diet, Reducing; Fenfluramine; Food Deprivation; Humans; Jejunoileal Bypass; Obesity; Obesity, Morbid | 1992 |
INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s.
Topics: Fenfluramine; Humans; Obesity; Recurrence; Time Factors; Weight Loss | 1992 |
Dexfenfluramine and appetite in humans.
Topics: Appetite; Energy Intake; Fenfluramine; Food; Humans; Satiation; Serotonin; Weight Loss | 1992 |
Appraisal of the clinical value of serotoninergic drugs.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Obesity; Serotonin; Weight Loss | 1992 |
51 trials available for fenfluramine and Weight Reduction
| Article | Year |
|---|---|
Effect of weight loss on lactate transporter expression in skeletal muscle of obese subjects.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Caloric Restriction; Citrate (si)-Synthase; Female; Fenfl | 2008 |
The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
Topics: Adult; Alcohol Drinking; Ambulatory Care; Dietary Carbohydrates; Double-Blind Method; Eating; Feedin | 1995 |
The comparison of four weight reduction strategies aimed at overweight diabetic patients.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet.
Topics: Adult; Body Composition; Diet, Reducing; Double-Blind Method; Energy Intake; Energy Metabolism; Fema | 1995 |
Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
Topics: Adolescent; Adult; Anthropometry; Body Composition; Body Constitution; Cardiovascular Diseases; Chol | 1995 |
Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.
Topics: Adolescent; Adult; Anthropometry; Body Temperature Regulation; Diet, Reducing; Double-Blind Method; | 1995 |
Dexfenfluramine reduces cardiovascular risk factors.
Topics: Apolipoproteins B; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Choleste | 1994 |
Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Fe | 1994 |
Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.
Topics: Adolescent; Adult; Aged; Blood Pressure; Body Mass Index; Caffeine; Double-Blind Method; Ephedrine; | 1994 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Diabetes Mellitus, Type 2; Fenfluramine; Glycated Hemoglobin; Humans; Weight Loss | 1994 |
Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
Topics: Adult; Blood Chemical Analysis; Body Temperature; Body Weight; Calorimetry, Indirect; Double-Blind M | 1993 |
Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 1993 |
The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity.
Topics: Adult; Female; Fenfluramine; Humans; Obesity; Weight Loss | 1996 |
[Efficacy and safety of dexfenfluramine treatment in obese adolescents].
Topics: Adolescent; Chromaffin Granules; Energy Intake; Female; Fenfluramine; Humans; Male; Obesity; Triglyc | 1996 |
The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; Female; Fenfl | 1995 |
Serotoninergic drug-induced weight loss in carbohydrate craving obese patients.
Topics: Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Energy Intake; Female; Fenfluramine; F | 1996 |
Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Double-Blind Method; Exercise; Female; Fenfl | 1996 |
The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial.
Topics: Adult; Aged; Body Mass Index; Drug Therapy, Combination; Female; Fenfluramine; Fluoxetine; Humans; L | 1996 |
Predictors of weight loss during treatment with d-fenfluramine.
Topics: Adult; Analysis of Variance; Appetite Depressants; Body Weight; Energy Intake; Female; Fenfluramine; | 1997 |
Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.
Topics: Adult; Affect; Appetite Depressants; Behavior Therapy; Feeding Behavior; Female; Fenfluramine; Human | 1997 |
Dexfentluramine in the treatment of juvenile obesity.
Topics: Blood Pressure; Female; Fenfluramine; Humans; Male; Obesity; Placebos; Selective Serotonin Reuptake | 1997 |
Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes Mellitu | 1997 |
Lower fat intake as a predictor of initial and sustained weight loss in obese subjects consuming an otherwise ad libitum diet.
Topics: Adult; Aged; Appetite Depressants; Body Mass Index; Dietary Fats; Exercise; Female; Fenfluramine; Hu | 1998 |
The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up.
Topics: Ambulatory Care; Appetite Depressants; Diabetes Mellitus; Dietetics; Female; Fenfluramine; Follow-Up | 1998 |
Gender difference in the effect of body composition on energy metabolism.
Topics: Abdomen; Adipose Tissue; Adult; Appetite Depressants; Basal Metabolism; Body Composition; Body Weigh | 1999 |
Pharmacologic induction of weight loss to treat type 2 diabetes.
Topics: Appetite Depressants; Behavior Therapy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetes M | 1999 |
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Topics: Adrenergic Agents; Adult; Appetite Depressants; Body Mass Index; Double-Blind Method; Echocardiograp | 1999 |
Initial weight loss as a predictor of response to obesity drugs.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Drug Therapy, Combination; Female; Fenfluramine; H | 1999 |
Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin?
Topics: Adult; Basal Metabolism; Blood Glucose; Body Mass Index; Diet, Reducing; Energy Intake; Energy Metab | 2000 |
Fasting insulin levels influence plasma leptin levels independently from the contribution of adiposity: evidence from both a cross-sectional and an intervention study.
Topics: Adipose Tissue; Adult; Body Composition; Body Weight; Cross-Sectional Studies; Diet, Reducing; Energ | 2000 |
Reduction of visceral adipose tissue during weight loss.
Topics: Adipose Tissue; Adult; Analysis of Variance; Body Weight; Diet, Reducing; Double-Blind Method; Femal | 2002 |
Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Intake; Female; Fen | 1992 |
Body weight evolution during dexfenfluramine treatment after initial weight control.
Topics: Adult; Body Weight; Diet, Reducing; Double-Blind Method; Energy Intake; Female; Fenfluramine; Humans | 1992 |
Hormone responses to fenfluramine and placebo challenge in endogenous depression.
Topics: Adult; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Depressive Disorder; Double-Blind Met | 1992 |
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fenfluramine; Follow-Up St | 1992 |
Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
Topics: Adult; Analysis of Variance; Cardiovascular Diseases; Feeding Behavior; Female; Fenfluramine; Humans | 1992 |
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
Topics: Adult; Behavior Therapy; Blood Pressure; Body Weight; Diet, Reducing; Double-Blind Method; Exercise; | 1992 |
Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
Topics: Adult; Behavior Therapy; Blood Pressure; Combined Modality Therapy; Diet, Reducing; Drug Therapy, Co | 1992 |
Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
Topics: Adult; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fem | 1992 |
Long-term weight control study. VI. Individual participant response patterns.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenflur | 1992 |
The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1992 |
Drug therapy after very-low-calorie diets.
Topics: Adult; Affect; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Energy Intake; Female | 1992 |
Fenfluramine and mental retardation.
Topics: Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Encopresis; Enuresis; Fenflurami | 1991 |
Serotonergic control of TSH and PRL secretion in obese men.
Topics: Adult; Diet, Reducing; Fenfluramine; Humans; Hypothyroidism; Male; Obesity; Prolactin; Receptors, Se | 1990 |
[Drug therapy of obesity--results of treatment with dexfenfluramine].
Topics: Adult; Female; Fenfluramine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1990 |
International trial of long-term dexfenfluramine in obesity.
Topics: Adult; Aged; Double-Blind Method; Female; Fenfluramine; Humans; Male; Middle Aged; Multicenter Studi | 1989 |
Treatment of seasonal depression with d-fenfluramine.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Depressive Disorder; Dietary Carbohydrates; Double | 1989 |
A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Hu | 1988 |
Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration.
Topics: Adult; Age Factors; Clinical Trials as Topic; Eating; Female; Fenfluramine; Humans; Hunger; Male; Mi | 1988 |
Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
Topics: Adult; Blood Cell Count; Blood Pressure; Double-Blind Method; Female; Fenfluramine; Humans; Male; Mu | 1988 |
Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
Topics: Clinical Trials as Topic; Double-Blind Method; Fenfluramine; Humans; Obesity; Time Factors; United K | 1988 |
44 other studies available for fenfluramine and Weight Reduction
| Article | Year |
|---|---|
Weight Loss Supplement-Induced Pulmonary Hypertension: A Decades Delayed Presentation of Fenfluramine-Phentermine.
Topics: Fenfluramine; Humans; Hypertension, Pulmonary; Obesity; Phentermine; Weight Loss | 2023 |
Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice.
Topics: Animals; Blood Glucose; Body Weight; Feeding Behavior; Fenfluramine; Gastric Bypass; Male; Mice, Inb | 2015 |
Is new hope on the horizon for obesity?
Topics: Anti-Obesity Agents; Bridged Bicyclo Compounds, Heterocyclic; Caloric Restriction; Fenfluramine; Hum | 2008 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Hum | 2010 |
A serotonin and melanocortin circuit mediates D-fenfluramine anorexia.
Topics: Animals; Anorexia; Fenfluramine; Male; Melanocortins; Mice; Mice, Inbred C57BL; Mice, Knockout; Neur | 2010 |
Greater than predicted decrease in energy expenditure during exercise after body weight loss in obese men.
Topics: Adult; Aged; Analysis of Variance; Body Composition; Energy Metabolism; Exercise; Female; Fenflurami | 2003 |
Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido.
Topics: Adult; Chemical and Drug Induced Liver Injury; Dietary Supplements; Drugs, Chinese Herbal; Female; F | 2003 |
Summaries for patients. Liver injury in 12 patients taking the herbal weight loss aids Chaso or Onshido.
Topics: Adult; Chemical and Drug Induced Liver Injury; Dietary Supplements; Drugs, Chinese Herbal; Female; F | 2003 |
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Appetite Depressants; Behavior, Animal; Biphenyl Compo | 2004 |
Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Dexfenfluramine; Female; Fenfluramine; Humans; Life Sty | 2004 |
Fenfluramine treatment in female rats accelerates the weight loss associated with activity-based anorexia.
Topics: Animals; Anorexia; Eating; Female; Fenfluramine; Motor Activity; Rats; Rats, Long-Evans; Weight Loss | 2005 |
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H | 2007 |
Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Chemistry, Pharmaceutical; Cyclobutanes; Drug and | 2007 |
Effect of aging and drug-induced weight reduction on rat vascular reactivity.
Topics: Administration, Oral; Aging; Animals; Aorta; Blood Glucose; Body Weight; Endothelium, Vascular; Fenf | 1993 |
Hypothalamic neuropeptides could mediate the anorectic effects of fenfluramine.
Topics: Animals; Appetite Depressants; Blood Glucose; Corticotropin-Releasing Hormone; Eating; Fenfluramine; | 1994 |
Effect of dexfenfluramine on fat mass distribution in a high-fat rat model.
Topics: Adipose Tissue; Animals; Dietary Fats; Disease Models, Animal; Fenfluramine; Male; Rats; Rats, Sprag | 1995 |
Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Diet, Reducing; Drug Therapy, | 1995 |
Tolerance to the anorectic effect of dexfenfluramine in rats: role of serotonin, cholecystokinin, and neuropeptide Y.
Topics: Animals; Appetite Depressants; Brain; Brain Chemistry; Cholecystokinin; Drug Tolerance; Eating; Fema | 1994 |
Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.
Topics: Adult; Dietary Carbohydrates; Dietary Proteins; Eating; Female; Fenfluramine; Fluoxetine; Humans; Mo | 1993 |
Dexfenfluramine influences dietary compliance and eating behavior, but dietary instruction may overrule its effect on food selection in obese subjects.
Topics: Adult; Diet, Reducing; Dietary Fats; Dietary Proteins; Eating; Energy Intake; Feeding Behavior; Fema | 1993 |
[Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
Topics: Adipose Tissue; Adult; Anthropometry; Body Composition; Combined Modality Therapy; Diet, Reducing; D | 1993 |
Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
Topics: Adult; Amino Acids; Appetite Depressants; Dietary Fats; Dietary Proteins; Female; Fenfluramine; Food | 1996 |
Dexfenfluramine and abdominal visceral fat.
Topics: Abdomen; Adipose Tissue; Appetite Depressants; Body Composition; Female; Fenfluramine; Humans; Male; | 1996 |
Iowa patients want new anti-obesity drug.
Topics: Appetite Depressants; Diet, Reducing; Fenfluramine; Humans; Obesity; Patient Education as Topic; Sel | 1996 |
Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups.
Topics: Adipose Tissue; Adult; Anthropometry; Appetite Depressants; Black or African American; Black People; | 1996 |
The hope and the hazards of using compliance data in randomized controlled trials.
Topics: Appetite Depressants; Data Interpretation, Statistical; Double-Blind Method; Fenfluramine; Follow-Up | 1998 |
The fen-phen finale: a study of weight loss and valvular heart disease.
Topics: Adult; Affect; Appetite; Behavior Therapy; Drug Therapy, Combination; Echocardiography, Doppler; Fem | 1998 |
After fen-phen.
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin | 1997 |
Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
Topics: Adult; Circadian Rhythm; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Combinat | 1999 |
Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
Topics: Appetite Depressants; Body Mass Index; Diet, Reducing; Drug Combinations; Echocardiography; Female; | 1999 |
Physical activity and low-fat diet: is it enough to maintain weight stability in the reduced-obese individual following weight loss by drug therapy and energy restriction?
Topics: Adult; Appetite Depressants; Body Mass Index; Calorimetry, Indirect; Cohort Studies; Diet, Fat-Restr | 1999 |
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug | 1999 |
The promotion effect of anorectic drugs on aflatoxin B(1)-induced hepatic preneoplastic foci.
Topics: Adipose Tissue, Brown; Aflatoxin B1; Amphetamine; Animals; Appetite Depressants; Biomarkers; Body Te | 1999 |
Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters.
Topics: Adult; Appetite Depressants; Depression; Eating; Feeding and Eating Disorders; Female; Fenfluramine; | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Metabolic fitness in active reduced-obese individuals.
Topics: Adult; Basal Metabolism; Cholesterol, HDL; Cohort Studies; Diet, Reducing; Energy Intake; Energy Met | 1999 |
Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up.
Topics: Adult; Appetite; Area Under Curve; Diet, Fat-Restricted; Energy Intake; Exercise; Fasting; Female; F | 2000 |
The relationship between health-related quality of life and weight loss.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Drug Therapy, Com | 2001 |
Increase in plasma pollutant levels in response to weight loss is associated with the reduction of fasting insulin levels in men but not in women.
Topics: Adipose Tissue; Area Under Curve; Blood Glucose; Body Mass Index; Energy Intake; Environmental Pollu | 2002 |
Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function.
Topics: Adult; Ambulatory Care; Day Care, Medical; Depressive Disorder; Female; Fenfluramine; Hospitalizatio | 1991 |
Hormonal responses to fenfluramine in depressed and control subjects.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Diazepam; Female; Fenfluramine; Humans; Hydrocortisone | 1990 |
Myocardial infarction associated with dextrofenfluramine.
Topics: Female; Fenfluramine; Humans; Myocardial Infarction; Weight Loss | 1990 |
Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine.
Topics: Adult; Appetite Depressants; Diet, Reducing; Energy Intake; Fenfluramine; Humans; Obesity, Morbid; W | 1989 |
Long term actions of d-fenfluramine in two rat models of obesity. I Sustained reductions in body weight and adiposity without depletion of brain serotonin.
Topics: Adipose Tissue; Animals; Brain Chemistry; Energy Intake; Female; Fenfluramine; Lipid Metabolism; Lip | 1989 |